A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer

Clinical trial NCT03745222 · TERMINATED

Trial details

NCT number: NCT03745222
Sponsor: Celgene
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2019-05-22
Primary completion: 2019-06-26
Enrollment: 1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.